Main Article Content
Abstract
Background: In the modern competitive world, cardiovascular challenges are becoming common and becoming responsible for early deaths. Myocardial Infarction (MI) is a predominant cause of pre-mature deaths. Numerous Procedures have been applied to evaluate MI risk. For the evaluation of MI risk, a separately developed MIRAT is employed. Even though significant strides have been achieved to reduce mortality, coronary artery disorders (CAD) remain the leading cause of death in many nations, making it one of the major health issues facing the world. Therefore, one of the most crucial health concerns in many nations, including Iran, may be the need to investigate risk and effective factors for CAD.
Objective: To evaluate the threat of Myocardial infarction among people in the middle age population using the MIRAT
Method: This is a prospective interventional study carried out over a length of 24 weeks after obtaining the institutional Human Committee approval. MIRAT was used in this research which includes 16 self-reporting questions covering age, gender, diabetic history, smoking history, records of hypertension, and family records of coronary heart assault prior 55 years of age etc., This information helps to evaluate the hazard of Myocardial infraction based on danger score criteria. In case the resulting points are greater than 10, considered patients are at greater threat of getting MI.
Results: Using the inclusion criteria, 100 subjects were involved in the research. 36 of them were women, while 64 of them were men. The ages 35 to 50 made up the bulk of the population, while 23% of people were from an agricultural background and 38% were from the business sector. Twenty-two (22%) of the 100 participants were found to possess a greater threat of developing MI.
Conclusion: The study's findings showed that the MIRAT can be used to foretell the possibility of time ahead of Myocardial infarction.
Keywords
Article Details
References
- 1. Chun CC, Chein HL, Cheng JL, et. al. Impact of Pharmacist Interventions on the Long-Term Clinical Outcomes in Patients with Myocardial Infarction. Acta Cardiologica Sin.2019; 35(3):290.
- 2. Garcia-OA, Sans-R, J., Ferrero-G, A., Alquezar-A, A., Sionis, A., & Ordóñez-L, J. Risk Assessment after ST-Segment Elevation Myocardial Infarction: Can Biomarkers Improve the Performance of Clinical Variables?. J clini med.2022;11(5):1266.
- 3. Peletidi A, Nabhani-GS, Kayyali R. The role of pharmacists in cardiovascular disease prevention: Qualitative studies from the United Kingdom and Greece. J Res Pharm Pract. 2019 [cited 2023 Mar 20];8:112-22
- 4. Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: A systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 2020 Jan;86(1):29-38.
- 5. Vivan WL, Libby MC, Winky JW, Ho WC, Carman KNg & Franco WC. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. BMC cardiovascular disorders. 2015;15: 178.
- 6. Azab AE, Elsayed ASI. Acute myocardial infarction risk factors and correlation of its markers with serum lipids. J Appl Biotechnol Bioeng. 2017;3(4):385-391.
- 7. Bhandari, Monika & Singh, Vikas & Venkatraman, Deepesh. A study of risk factors for acute myocardial infarction in patients below 35 years in eastern India. Nigerian Journal of Cardiology. 2017;14:84.
- 8. Zodpey, S. P., Shrikhande, S. N., Negandhi, H. N., Ughade, S. N., & Joshi,P. P. Risk factors for acute myocardial infarction in central India: a case-control study. Indian journal of community medicine: official publication of Indian Association of Preventive & Social Medicine. 2015;40(1): 19–26.
References
1. Chun CC, Chein HL, Cheng JL, et. al. Impact of Pharmacist Interventions on the Long-Term Clinical Outcomes in Patients with Myocardial Infarction. Acta Cardiologica Sin.2019; 35(3):290.
2. Garcia-OA, Sans-R, J., Ferrero-G, A., Alquezar-A, A., Sionis, A., & Ordóñez-L, J. Risk Assessment after ST-Segment Elevation Myocardial Infarction: Can Biomarkers Improve the Performance of Clinical Variables?. J clini med.2022;11(5):1266.
3. Peletidi A, Nabhani-GS, Kayyali R. The role of pharmacists in cardiovascular disease prevention: Qualitative studies from the United Kingdom and Greece. J Res Pharm Pract. 2019 [cited 2023 Mar 20];8:112-22
4. Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist-led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: A systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 2020 Jan;86(1):29-38.
5. Vivan WL, Libby MC, Winky JW, Ho WC, Carman KNg & Franco WC. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. BMC cardiovascular disorders. 2015;15: 178.
6. Azab AE, Elsayed ASI. Acute myocardial infarction risk factors and correlation of its markers with serum lipids. J Appl Biotechnol Bioeng. 2017;3(4):385-391.
7. Bhandari, Monika & Singh, Vikas & Venkatraman, Deepesh. A study of risk factors for acute myocardial infarction in patients below 35 years in eastern India. Nigerian Journal of Cardiology. 2017;14:84.
8. Zodpey, S. P., Shrikhande, S. N., Negandhi, H. N., Ughade, S. N., & Joshi,P. P. Risk factors for acute myocardial infarction in central India: a case-control study. Indian journal of community medicine: official publication of Indian Association of Preventive & Social Medicine. 2015;40(1): 19–26.